Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) are neurotropic alphaherpesviruses that establish lifelong latency in sensory ganglia and are capable of periodic reactivation. While each virus has been independently associated with neurological disease, co-infection and co-reactivation in human trigeminal ganglia (TG) are common and may exacerbate neurological and neurodegenerative outcomes. However, the mechanisms by which latent or subclinical activity of one virus may influence the pathogenic potential of the other remain poorly defined. Emerging evidence suggests that extracellular vesicles (EVs) released from VZV- infected neurons contain host and viral cargo that can modulate immune responses in neighboring cells. This project tests the central hypothesis that non-infectious EVs from VZV-infected neurons suppress innate immune responses in peripheral barrier tissues, such as the olfactory epithelium, thereby facilitating greater HSV-1 replication, spread, and neurovirulence. This immune suppression may accelerate HSV-1 neuroinvasion and increase the risk of CNS-related complications. Furthermore, we hypothesize that restoring interferon signaling, specifically through recombinant IFN-β treatment, will mitigate VZV EV- induced HSV-1 reactivation and preserve latency. In Aim 1A, we will determine how VZV-derived EVs alter mucosal and olfactory immune responses to increase susceptibility to primary HSV-1 infection. We further identify novel mechanisms of packaged VZV viral proteins (IE62) and their effects with co-infection of HSV-1 in vitro. In Aim 2A, we will evaluate whether VZV EV exposure is sufficient to induce HSV-1 reactivation from latency in vivo. In Aim 2B, we will test whether intranasal interferon-beta (IFN-β) supplementation can restore innate immune tone and suppress VZV EV-mediated HSV-1 reactivation. By defining how non-infectious viral signals alter antiviral immunity and viral latency, this research will uncover a novel mechanism of virus-virus interaction that may contribute to recurrent or more severe herpesvirus infections. Given increasing evidence linking herpesvirus reactivation to neuroinflammatory and neurodegenerative diseases, these findings may identify new therapeutic strategies to protect vulnerable populations and preserve long-term neurological health. Importance of Research: This study will systematically evaluate the molecular and cellular homeostatic mechanisms perturbed by VZV and HSV-1 interactions in vivo, contributing to an understanding of immune dysfunction and CNS neuroinvasion. Our interdisciplinary team with expertise in HSV-1 infection and neuroscience (Dr. Niemeyer), VZV infection and extracellular vesicle biology (Dr. Bubak), and olfactory epithelium pathology (Dr. Santoro) is uniquely equipped to complete this study.
Grant Summary
Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $429K for university, nonprofit, healthcare org. Applications are due 2028-05-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $429K
2028-05-31
- 1Confirm your organization is eligible for Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence: Frequently Asked Questions
Who is eligible for the Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence?
Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence provide?
Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence provides up to $429K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence deadline?
Applications for Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence are due 2028-05-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence?
To apply for Non-Infectious VZV EVs as a novel modulator of HSV-1 Neurovirulence, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.